

**For immediate release**

**4 September 2023**

**ANGLE plc ("the Company")**

**LAUNCH OF PORTRAIT FLEX CIRCULATING TUMOR CELL ASSAY**

***The Portrait Flex assay provides tailored analyses performed as a service by ANGLE's Onc-ADaPT™ laboratories***

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumor cell (CTC) diagnostic solutions for the research and diagnostic oncology market, is pleased to announce the launch of its Portrait™ Flex CTC assay\*. The assay is provided as a service from ANGLE's Onc-ADaPT™ GCP-compliant laboratories and conducted by an expert team with over 10 years' experience in CTC analysis.

CTCs captured and harvested using ANGLE's Parsortix® technology are subsequently enumerated and characterised with the Portrait Flex assay. Samples are analysed using immunofluorescence staining for epithelial, mesenchymal, blood lineage and nuclear markers, with the opportunity to include an additional biomarker tailored to customer needs. Examples of clinically relevant CTC biomarkers that have been researched using Parsortix technology and published in peer-reviewed publications include HER2, PIK3CA, PD-L1, EGFR, BRAF, AR-V7 among others.

The Portrait Flex assay has an analytical sensitivity\*\* of >93%, and an analytical specificity\*\* of >95% for both epithelial and mesenchymal markers. Data from the analysis of clinical samples from 16 metastatic breast cancer patients identified CTCs in 81% of patients, with 38.5% of the CTC-positive patients having ≥1 CTC with high HER2 levels highlighting the capability to assess current HER2 status in breast cancer patients. Of the patients with CTCs, approximately half showed a mesenchymal only phenotype, while the others showed a mixed phenotype, highlighting the importance of Parsortix epitope-independent isolation of CTCs.

Combining the use of the Parsortix technology and the Portrait Flex assay allows for testing that is specific to customer needs and can enhance their clinical trial evaluations. ANGLE is offering a flexible, full-service solution to help unlock precision medicine for patients.

**ANGLE Chief Commercial Officer, Brett Swansiger, commented:**

"I am pleased to announce the launch of our new Portrait™ Flex assay in our Onc-ADaPT™ clinical laboratories, the first of a number of assays that we will be bringing to market in the coming months for the benefit of our biopharma customers. This service, provided by a highly experienced team, can provide valuable data for clinical trials and contribute to the advancement in personalized cancer care."

**ANGLE Founder and Chief Executive, Andrew Newland, added:**

"To support adoption of its technology by adding "content", ANGLE has been developing a menu of imaging assays and molecular assays to analyse the CTCs harvested by the Parsortix system. These assays support both ANGLE's pharma services business and product business for third-party customers."

\*For Research Use Only. Not For Use in Diagnostic Procedures.

\*\*Analytical sensitivity = Proportions of spiked cells known to express the marker(s) of interest which were marker positive in the assay. Analytical specificity = Proportions of spiked cells known to NOT express the marker(s) of interest which were marker negative in the assay.

**For further information:**

<b>ANGLE plc</b> Andrew Newland, Chief Executive Ian Griffiths, Finance Director Andrew Holder, Head of Investor Relations	<b>+44 (0) 1483 343434</b>
<b>Berenberg (NOMAD and Joint Broker)</b> Toby Flaux, Ciaran Walsh, Milo Bonser	<b>+44 (0) 20 3207 7800</b>
<b>Jefferies (Joint Broker)</b> Thomas Bective, Shaam Vora	<b>+44 (0) 20 7029 8000</b>
<b>FTI Consulting</b> Simon Conway, Ciara Martin Matthew Ventimiglia (US)	<b>+44 (0) 203 727 1000</b> <b>+1 (212) 850 5624</b>

For Frequently Used Terms, please see the Company's website on <https://angleplc.com/investor-relations/glossary/>

**Notes for editors**

**About ANGLE plc**

ANGLE is a world-leading liquid biopsy company with innovative circulating tumor cell (CTC) diagnostic solutions for the research and diagnostic oncology market using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumor cell (CTC) harvesting technology known as the Parsortix<sup>®</sup> system enables complete analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix<sup>®</sup> system and associated consumables. The clinical services business is offered through ANGLE's GCP-compliant laboratories in the UK and the United States. Services include custom made assay development and clinical trial testing for pharma.

Over 80 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit [www.angleplc.com](http://www.angleplc.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFFFSIAAIVIV